Literature DB >> 25776840

Qingre quyu granule stabilizes plaques through inhibiting the expression of tenascin-C in patients with severe carotid stenosis.

Yi Wang1, Wen-li Cheng, Yong Wang, Jing-pin Peng, Jie Yuan, Li Chen, Lin Pan, Hong Li, Jian Guo.   

Abstract

OBJECTIVE: To investigate the therapeutic effects of Qingre Quyu Granule (QQG) on the patients with severe carotid stenosis, and to explore the mechanism of it.
METHODS: Ninety-six patients with severe carotid stenosis were enrolled in the study and were classified into a QQG group (n=48) and a control group (n=48) randomly using consecutively numbered envelopes. The patients in the QQG group were given QQG and Western medicine, those in the control group were given Western medicine merely, the course of treatment was 16 weeks. All patients went through endarterectomy after treatment. Plaques were subjected to the analysis of CD3, CD68, soluble intercellular adhesion molecule 1 (ICAM-1), matrix metalloprotease-9 (MMP-9), CD40L, tenascin-C, and collagen content lipid content by immunohistochemistry or polarized light analysis.
RESULTS: By the end of experiment, the expressions of CD3, CD68, ICAM-1, MMP9, CD40L and tenascin-C on the plaques were statistically significant lower in the QQG group compared with the control group(P<0.01). The lipid content of the plaque was also significantly lower in the QQG group compared with the control group (P<0.01). The interstitial collagen in the tissue sections of the plaques was also significantly higher in the QQG group in comparison with the control group (P<0.01).
CONCLUSION: QQG could stabilize carotid artery plaques through inhibiting pro-inflammation factors and restraining the tenascin-C and MMP9 pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25776840     DOI: 10.1007/s11655-015-2161-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  18 in total

Review 1.  Platelets in atherosclerosis.

Authors:  D Lievens; P von Hundelshausen
Journal:  Thromb Haemost       Date:  2011-10-20       Impact factor: 5.249

Review 2.  Leukocyte-derived microparticles in vascular homeostasis.

Authors:  Anne Angelillo-Scherrer
Journal:  Circ Res       Date:  2012-01-20       Impact factor: 17.367

3.  Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.

Authors:  Maren Luchtefeld; Nele Bandlow; Uwe J F Tietge; Karsten Grote; Josef Pfeilschifter; Marietta Kaszkin; Sabine Beck; Helmut Drexler; Bernhard Schieffer
Journal:  Atherosclerosis       Date:  2006-10-27       Impact factor: 5.162

4.  North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress.

Authors: 
Journal:  Stroke       Date:  1991-06       Impact factor: 7.914

5.  [Effect of qingre quyu granule on the vulnerable atherosclerotic plaque of carotid artery in patients with stable coronary artery disease].

Authors:  Wen-li Cheng; Yong Wang; Zhe Cai
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2009-12

Review 6.  The role of tenascin C in cardiovascular disease.

Authors:  Jonathan Golledge; Paula Clancy; Jane Maguire; Lisa Lincz; Simon Koblar
Journal:  Cardiovasc Res       Date:  2011-06-28       Impact factor: 10.787

7.  Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque.

Authors:  K Wallner; C Li; P K Shah; M C Fishbein; J S Forrester; S Kaul; B G Sharifi
Journal:  Circulation       Date:  1999-03-16       Impact factor: 29.690

Review 8.  Autophagy in atherosclerosis: a potential drug target for plaque stabilization.

Authors:  Dorien M Schrijvers; Guido R Y De Meyer; Wim Martinet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-12       Impact factor: 8.311

9.  Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases.

Authors:  A Siri; V Knäuper; N Veirana; F Caocci; G Murphy; L Zardi
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

Review 10.  Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.

Authors:  R Preston Mason
Journal:  Vasc Health Risk Manag       Date:  2011-06-24
View more
  1 in total

1.  Tenascin-c renders a proangiogenic phenotype in macrophage via annexin II.

Authors:  Zhiyang Wang; Qi Wei; Liang Han; Keqing Cao; Tianfeng Lan; Zhenjie Xu; Yingjuan Wang; Yuan Gao; Jing Xue; Fei Shan; Jun Feng; Xin Xie
Journal:  J Cell Mol Med       Date:  2017-08-30       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.